Specification of functional cranial placode derivatives from human pluripotent stem cells
AssigneeMemorial Sloan Kettering Cancer Center
InventorsStuart Chambers, Lorenz Studer, Zehra Dincer, Bastian Zimmer
Life of this patent
Estimating the term…
Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsStuart Chambers, Lorenz Studer, Zehra Dincer, Bastian Zimmer
Estimating the term…
Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.
A method for inducing differentiation of cells, comprising:
A method for inducing differentiation of cells, comprising
A method of inducing differentiation of cells, comprising contacting a plurality of cells expressing SIX1 and PAX6 with
A composition comprising cells that express one or more protein selected from the group consisting of SIX1, PAX3, AP2, ISL1, HNK1, BRN3A, PERIPHERIN, GLUTAMATE, RUNX1, RET, TRK receptors, NTRK1, NTRK2, sodium channels, SCN9A, SCN10A, SCN11A, classic pain receptors, TRPV1, TRPM8, P2X3, CD40, CD57, CD81, CD147, and GD2.
A composition comprising cells that express one or more protein selected from the group consisting of SIX1, PITX1, PITX2, SIX6, LHX3, LHX4, TBX19, PIT1, GATA2, CGA, FSH, ACTH, GH, Ki67, Sox2, and AP2.
A composition comprising cells that express one or more protein selected from the group consisting of SIX1, PITX3, αβ-crystalline, and AP2.
A method of treating a subject comprising grafting a cell to a subject in need thereof, wherein
Dependencies are inferred from the claim text.